▲ Peaking
Business
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis maintains guidance and long-term goals despite absorbing multi-billion dollar writedowns from trial setbacks.
Del-Desiran
2 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✗
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
A major Novartis shareholder is demanding a board overhaul following a series of costly drug trial setbacks and strategic failures.